# Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial

> **NCT05764746** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Muhimbili University of Health and Allied Sciences** · enrollment: 384 (estimated)

## Conditions studied

- Uncomplicated Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** Artemether-lumefantrine and Amodiaquine Drug Combination
- **DRUG:** Artemether-lumefantrine then Artesunate amodiaquine
- **DRUG:** Artemether-lumefantrine

## Key facts

- **NCT ID:** NCT05764746
- **Lead sponsor:** Muhimbili University of Health and Allied Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 384 (ESTIMATED)
- **Last updated:** 2024-12-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764746, "Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05764746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*